Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
They may be cheap, but there is no volume because this piece of shiat CEO doesn’t update anyone about the company or it’s status since October 2023 and doesn’t file financials on-time on top of that… So what good is it to have cheap shares with no share volume trading???
Since you seem to have the IR persons ears and attention, did you ask about who is actually doing the financials now that Ms Zia Choe has moved on from STK Financial to another company as per the announcement that was PR’d back in January 2024???
If you buy these cheap shares you make a double and you look like a genius if he doesn't file well you didn't lose to much and he may still file and get it done
Wow glad you boy's got that off your chests but this is just like going to a casino game don't bet the farm just play the game take your wins and losses and go home still money to be made
The more time passes the more I am of the belief in that this was nothing more than your typical “Nigerian Scammer”!!!!
But yet when filings are ever produced, we probably will see more debt added to the outstanding which by the way was supposed to have been extinguished years ago as per a certain PR that if everyone remembers kicked off the billion share volume day…
Maybe they sent them using Morse code??
ALSO 6 WEEKS AGO SAID:THE COMPANY IS ON TRACK TO BEGIN SHIPPING OVERSEAS IN MARCH.WHERE IS THE UPDATE???
ViaDerma
@viaderma
·
Jan 31
$VDRM Update: We received very positive feedback and have successfully completed the stability requirements for the Vitastem Ultra bacitracin formula. The company is on track to begin shipping
@vitastem
overseas in March.
6 WEEKS AGO THEY SAID???$1,2 MILLION??LOL.
ViaDerma
@viaderma
·
Feb 1
$VDRM Update: The company has received licensing payments totaling $1.2M and will be updated into our financials accordingly. More updates to follow.
THE LYING DIRTY BAGS SAID 7 WEEKS AGO?????WHERE ARE THE FILINGS THAT GOT SUBMITTED??AND INTERNATIONAL DISTRIBUTIONS COMING SOON???
ViaDerma
@viaderma
Update: $VDRM filings have been submitted to #OTCMarkets. Further updates on stability testing requirements completion and moving forward with international sales distribution for
@vitastem
are coming soon.
3:40 PM · Jan 23, 2024
·
1,734
View
Dr has wound pros and Biogenx. He obviously doesn’t care about Viaderma Otiko uses this company to stock his other companies and Jack Brewer’s and never pays the bill for the product. VDRM is not even getting the $$$ when product is being sold off THEIR website. Couple that with never closing 1 deal in the last 7 years.MAJOR SCAM!!!!
Maybe we C a little spike within 2 weeks
This game will continue I will ride it out
gameccks1 You can only go by what U were told Thanks
The $343K, I think, forgiven, accounts receivable still sticks in my craw, too, because he promised multiple quarters and maybe a couple of years, that the payment was coming, to ultimately right it off as advertising, if I recall correctly. Once again, that cannot be undone. There is only a polar option: Sell or Wait for the outcome.
The skepticism is totally understandable and deserved, based on multiple years and multiple unrealized, game-changing forecasts, and subsequent silence, followed by pivots to opposite (foreign to US, and US to foreign) by the Dr. Like everyone, he cannot go back and undo things in the past. He can only fulfill forecasts and seek to rebuild credibility going forward. The next 2-4 weeks are once again extremely important opportunity to that end. Do the reports get finished and issued as forecast? That will be easy to verify. Does the recently re-confirmed (Jan 31st), promised initiation of large oversees shipments begin this month or not? Will there be communication one way or the other? Those are perpetually the types of questions with the Dr. However, if, and it is a VERY BIG IF, the whole perspective will be different, FINALLY.
But maybe the Dr can loan himself some money again like in one of those past Quarterly reports (Like the one where I believe it was $300k +/-) that he stated and then in a couple quarterlies later stated that the loan had been forgiven by the company……
Did you cast your vote in favor of forgiving his debt???
Then he claims the $300k loan was not for his new business venture WoundPros…..
You know what they say - If it sounds like a scam or smells like a scam, then 9 times out of 10, it’s a scam. Now I hope I am wrong since this would be the 2nd of 2 scams I have been invested unfortunately in during my lifetime. Only reason I thought it might have been different here was when people I know used the product for ailments and luved it (except for the dark brown staining)…..
Or wait…… Maybe it’s the Dr Otiko who told investors that he had a HUGE HOSPITAL ORDER waiting to be issued a Purchase Order from????
Or the Dr Otiko who promised a quick turnaround on a hair regrowth formula???
Or the same Dr Otiko the company received $600k from Dubai?
Is that the same Dr Otiko who PR’d that all outstanding debts were paid off and wiped from the books????
Starting to smell very “fishy” it you ask me. From all the BS that has transpired in the past to now we are supposed to believe the IR guy or Dr Otiko???
VDRM VWAP=$.0081 VOLUME=1.2mm Bid-side 8x
3/13. VDRM VWAP=$.0087 VOLUME=1.7mm Bid-side 5x
That’s the same shit you said you were told at end of last month no???
Diamond hands, of course but I aint adding these levels
Looks like dorka and his minions are out. IMO
Risk/reward looks better if you can buy in the .007s
GLTA
VDRM VWAP=$.0087 VOLUME=1.7mm Bid-side 5x
BRO YOU ARE GOING TO RIDE IT ALL THE WAY TO ZERO BID??SAY BRO.OFCOURSE ORCA.
LOL. hope so. GL
mark5050 Good 4 U this show ain't over.
The House I live in is only 450K sorry
Then, I ain’t a real one then. OTIKO isn’t going to see a penny more From until I hear from his butt
Added. Go VDRM!!!!
I AM LOOKING FOR MY 500K$ BET WHEN WE FALL IN THE EXPERT MARKET.START SELLING YOUR HOME.
Any real trader will buy on the dip $$$
HEY SLOPOLOGY,WE ARE HEADING BELOW .008 SOON IT SEEMS.OTIKO GOT US BIG TIME.
Perhaps, but why do you then waste your posts there talking about IHUB?
I find it hilarious how you brag about volume of stocks tanking, as if this is a good thing.
Are you happy to see the share price fall faster?
VDRM VWAP=$.0088 VOLUME=2.2mm
He is NOT the brightest bulb on the tree.
You will be left behind.
Followers
|
617
|
Posters
|
|
Posts (Today)
|
1
|
Posts (Total)
|
74423
|
Created
|
10/27/08
|
Type
|
Free
|
Moderators |
ViaDerma's proprietary transdermal delivery system allows for rapid mass transfer of the pharmaceutical active ingredient across the skin and into the body to provide immediate localized therapy.
The technology allows transfer of chemicals through the stratum corneum (outer layer of skin) with a diffusion constant which is 10,000 times higher than the diffusion constant which characterizes water movement through the stratum corneum.
This enables ViaDerma to pair almost any active ingredient with the technology and provide rapid transport of the medicine right to the site of action.
The first product is a broad spectrum tetracycline-based topical antibiotic is the only antibiotic in the world that kills bacteria both a physical and a chemical mechanism. All known antibiotics (other than ours) primarily use only a chemical mechanism of kill. The physical mechanism of kill is a key feature of what we call Rapid Active Ingredient Delivery System (RAIDS). One result of RAIDS is that tetracycline is carried in higher concentrations, more quickly, to and through the cell walls, where the tetracycline can become more effective than if conventional antibiotics were used. Conventional antibiotics require more time (usually prescribed for 5 to 7 days for best results), whereas our tetracycline-based products usually produce desirable results in 24 hours (or less) because of the RAIDS effect.
A second important result of RAIDS is that the topical antibiotic kills all harmful Gram positive and Gram negative bacteria that have been available for testing. We believe this is the world’s strongest broad-spectrum topical antibiotic available.
The potential commercial impact is immense. Drug developers believe it takes much longer for bacteria to develop drug resistance to a physical kill mechanism. This is because it is relatively easy for bacteria to change their response to a chemical threat, but it takes numerous generations for bacteria to grow a new kind of cell wall structure to respond to a physical threat.
Our novel approach to overcome drug resistance of antibiotics is designed to sustain the effectiveness of antibiotics and other topical drugs for many years. This gives new topical drug products a longer useful lifetime and therefore more commercial value. This technology, when licensed to larger pharmaceutical companies, may provide stronger incentive for the discovery and development of new antimicrobial drugs. In recent years, the dearth of new antibiotics has been largely due to the uncertain new-drug commercial lifetime which is diminished when bacteria develop immunity to that drug.
In addition the technology can be licensed to other companies to convert existing oral drugs to transdermal medications extending the profitably of the existing drug.
We are developing products in the following fields of use;
Treats all types of bacteria including MRSA, VRE and other flesh eating bacteria. Fights drug resistant bacteria. $6B/year global market.
Onychomycosis, a fungal infection of the toenails, is a major health problem. It is estimated that there are in excess of 40 million sufferers with this condition in the USA. It is a problem throughout the world. A recent European study showed that the prevalence of Onychomycosis may be as high as 26.9%. Fungal resistance can occur when the oral antifungal agents are used on a long-term basis. Topically applied antifungal drugs may work somewhat better adjunctive to surgical removal or chemical dissolution of the nail plate. Yet, this often ineffective and traumatic procedure leaves the subject without a nail for months at risk for re-infection. Given the limitations of current treatment options in this $3B market, there is a great need for a simple, nontoxic and effective alternative treatment. Estimated Global prevalence rate: 140 million.
Treats symptoms of Influenza which is a$4B/ year global market: Common
Diabetic foot wounds.
Per 3/8/18 PR: ViaDerma’s technology is currently being used in Elixr Cannabis products; Topical Balm, Topical Serum and Topical Spray. Sales have begun in Canada.
Per 12/7/17 PR: The Company has signed an MOU and will start production of its Patent Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent #62466209, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent # 62433964 for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinary uses. The Company would combine its proprietary solutions with CBD's and other natural products that treat psoriasis, fibromyalgia for pain and other ailments.
Per 1/23/18 PR: The Company has also a licensing and distribution agreement in place with its Canadian partners to produce a CBD Topical Serum, which has a 92% absorption rate powered by ViaDerma's Patent Pending Dual Carrier Technology. The CBD and Terpene profile (enriched with specific essential oils and vitamins C, and D) is crafted to alleviate Chronic Dry Skin, Psoriasis, Eczema, Rosacea, and many other skin conditions. The serum has anti-inflammatory, anti-bacterial, and chronic pain relief properties that are absorbed by the skin and provide overall healing benefits. Sales are expected to begin in the first quarter of 2018 and are projected to generate approximately $2 million annual revenues.
The Patented Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinarian uses. The Company would combine its proprietary solutions with CBD's and other natural products that treat psoriasis, fibromyalgia for pain and other ailments. The Company plans to continue to expand its (IP) "Intellectual Property Portfolio" in 2018.
CBD is a compound found in the Cannabis family of plants such as hemp. CBD is combined into our topical body care products like Elixr's Topical Balm, Serum, and Spray.
CBD is an antioxidant. Antioxidants protect our skin from damaging exposure to smoke, UV rays, and environmental pollutants. Cannabinoid receptors are located all throughout the skin, Topical CBD products interact with those receptors resulting homeostasis and healing. Studies show that CBD can help treat an array of skin conditions such as eczema, psoriasis, rosacea, and acne.
"What is Intellectual Property?" - A Publication by the World Intellectual Property Organization -
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |